Circle Pharma Announces Appointment of David Spellmeyer, PhD, as Chief Scientific Officer

2017-11-20T16:35:38+00:00 November 20th, 2017|Press Releases|

SOUTH SAN FRANCISCO, Calif. – (BUSINESS WIRE) – Circle Pharma, Inc., a developer of macrocycle therapeutics, today announced that David Spellmeyer, PhD, has been appointed as its chief scientific officer.

“His deep experience in rational drug design and discovery is an excellent fit for Circle as we extend our platform for macrocycle discovery and advance our therapeutic pipeline towards the clinic.”

Dr. Spellmeyer brings over 25 years of broad industrial experience to […]

Circle Pharma announces expansion of Series A financing and appointment of James C. Lu to its board

2017-09-25T14:41:44+00:00 April 5th, 2017|Press Releases|

Funds will be used to advance Circle’s computational and synthetic chemistry platform for macrocyclic peptide therapeutics Circle Pharma, Inc. today announced that it has completed an expansion of its Series A financing, with new investors W.I. Harper Group, Elements Partners, LLC, Whitesun Healthcare Ventures Limited and LifeForce Capital joining the round. Mission Bay Capital led Circle’s Series A, with Pfizer Inc. (NYSE:PFE), ShangPharma Investment Group, Ltd. and a syndicated group of in […]

Circle Pharma announces Series A financing and appoints Walter H. Moos, Ph.D., to its board

2017-09-25T09:59:00+00:00 December 21st, 2016|Press Releases|

Circle Pharma, Inc. today announced a Series A financing round in which it has issued over $4.5M of shares of Series A Preferred Stock. The financing was led by Mission Bay Capital, with Pfizer Inc. (NYSE:PFE), ShangPharma Investment Group, Ltd. and a syndicated group of individual investors joining the round. In connection with the financing, Walter H. Moos, Ph.D., representing ShangPharma, has joined the Circle Board of Directors.

“We are delighted with the participation of such high calibe […]

Circle Pharma enters into an agreement with Pfizer to build screening library of macrocyclic peptides

2017-09-25T12:43:52+00:00 September 12th, 2016|Press Releases|

CirclePharma, Inc., today announced that it will apply its computational design and synthetic chemistry platform to design and create a physical screening library of novel macrocyclicpeptides. Once completed, the library is initially expected to comprise several hundred macrocycles that will be designed to potentially disrupt bioactive conformations commonly found in protein-protein interactions known to drive disease processes, and will deploy backbone scaffolds screened in silica for intrinsic […]

Circle Pharma Announces Appointment of Co-Founder Prof. Matthew Jacobson to Department Chair

2017-09-25T12:45:19+00:00 January 19th, 2016|Press Releases|

Circle Pharma, Inc., today announced that co-founder Prof. Matthew Jacobson has been appointed Chair of the UCSF Department of Pharmaceutical Chemistry.
“This is a terrific recognition of Matt’s exceptional accomplishments as a scientist and his passionate commitment as an educator,” said David J. Earp, JD, PhD, Circle’s President and CEO. “We are very appreciative of the guidance and leadership that our two co-founders – Matt Jacobson and Scott Lokey – continue to provide to Circle.”

Circle Pharma Announces Receipt of Additional Seed Investment, and Relocation to New Laboratory Facility

2017-09-25T10:00:43+00:00 January 7th, 2016|Press Releases|

Circle Pharma, Inc., today announced that it has extended its seed funding round with an investment from ShangPharma Investment Group Limited. In conjunction with this investment, Circle has relocated to office and laboratory space in South San Francisco.

“The addition of laboratory operations to our computational chemistry platform marks the next stage of Circle’s development,” said David J. Earp, J.D., Ph.D., Circle’s President and CEO, “and we have now initiated work on Circle’s internal p […]

Circle Pharma Announces Receipt of Seed Funding and Initiation of Two Collaborations

2017-09-25T10:02:04+00:00 September 22nd, 2014|Press Releases|

Circle Pharma, Inc., a newly created, early-stage biotechnology company, today announced that it has received seed funding from Pfizer Inc. and QB3’s seed-stage venture fund, Mission Bay Capital, LLC, and has initiated two collaborations with Pfizer to develop cell permeable macrocyclic peptide therapeutics.

“We are very pleased to have launched Circle with the backing of Pfizer and Mission Bay Capital, and to have initiated two exciting collaborative projects with Pfizer,” said David J. Earp […]